Where To Buy Peptides  ·  Adipotide · Safety

Adipotide side effects

Adipotide: the side effect lists you find online are extrapolated from ten rhesus monkeys dosed for 28 days in 2011. The human trial that was meant to produce a real safety profile enrolled four people and ended without posting results.

WTBP Research Team Updated 2026-11-07 8 min read 6 cited sources

Search adipotide side effects and you get confident lists. What sits under them is one 2011 primate study and a human trial that enrolled four people and posted nothing.

The short answer. No human adverse event data for adipotide has ever been published.

Adipotide has no published human safety data. The record is one monkey study from 2011. Kidney markers rose in those animals at higher doses. The human trial enrolled four people, then stopped. No results were ever posted. So the side effect list is mostly blank.

What the adipotide safety record actually contains

It contains three things. A mouse paper. A monkey paper. A registry entry.

That is the whole file. There is no published human adverse event table for this compound. Not a small one. None.

Everything written about adipotide side effects in people is inference. It is borrowed from animals, or from forum reports that nobody collected, counted or verified.

For what the efficacy side of that same file looks like, see adipotide before and after.

The kidney signal, and where it came from

The one real toxicity finding in the adipotide literature is renal, and it is from the monkeys.

In the 2011 study, kidney markers moved with dose. Creatinine rose in animals given more than 0.25 mg/kg. The kidney, not the fat, was the organ that set the ceiling.

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Barnhart et al., Science Translational Medicine, 2011 (paper title)

Read the title and you can see what the paper was written to report. The weight loss and the insulin result are in the headline. The renal findings are in the body of the work, and they are the reason the dose question was never simple. The dosage page lays out what each study administered.

Two limits matter here. The exposure was 28 days long. The species was not human. Nothing in the published record extends past either boundary.

Why the mechanism predicts a toxicity problem

Adipotide does not signal. It kills.

The design pairs a homing sequence, which seeks prohibitin on the blood vessels feeding white fat, with a short proapoptotic sequence that tells cells to die. Starve the fat tissue of its blood supply and the fat goes with it. The 2004 Nature Medicine paper says so in its title.

Reversal of obesity by targeted ablation of adipose tissue.

Kolonin et al., Nature Medicine, 2004 (paper title)

Ablation is the word. That is a cytotoxic strategy borrowed from cancer research, which is also why the first human study ran in oncology patients rather than in healthy volunteers.

Targeting is never perfect. A peptide that reaches the kidney and retains any of its killing function will do there what it does in fat. The renal numbers in the monkeys are consistent with that, and the compound is cleared renally in the first place.

Fat-targeted delivery research did continue, in other formats. A 2022 paper in Advanced Science describes nanoparticles built to target fat and liver tissue at the same time. That is a different construct with a different safety question, and it tells you nothing about the vial on sale. The mechanism story is set out in full in the adipotide complete guide.

What happened to the human trial

NCT01262664 was the study that would have produced a human side effect list. It was a Phase I evaluation of a single cycle, in patients with metastatic prostate cancer and obesity.

It opened at 0.03 mg/kg, a small fraction of what the monkeys received. It enrolled four people. The registry lists it as terminated.

Terminated. No results posted.

ClinicalTrials.gov record, NCT01262664

No publication followed. The registry does not carry an outcome table, so the public record contains no dose-limiting toxicity, no adverse event counts, and no laboratory data from those four participants. Fifteen years on, nothing has replaced it.

A terminated trial with no posted results is not a clean safety record. It is an empty one. The two are easy to confuse and they are not the same thing.

Which adipotide side effects have never been measured

This is the part the lists skip. Here is what the published record does not contain for humans.

Saying “adipotide may cause kidney injury, nausea and dehydration” sounds like a safety profile. It is a guess dressed as one. The honest sentence is shorter: in humans, the frequency and severity of every adipotide side effect is unknown.

How that compares to compounds with real safety databases

The useful contrast is not between adipotide and another research peptide. It is between adipotide and the obesity drugs that completed trials and published their harms.

CompoundHuman safety recordMeasured weight change
AdipotidePhase I terminated, four enrolled, no results postedNone published in humans
TirzepatidePhase III, SURMOUNT-122.5%
RetatrutidePhase 224.2%

Those two incretin programs enrolled thousands of people and reported their adverse events in the New England Journal of Medicine. Adipotide reported four enrollments and silence. That gap is the finding, not a footnote to it.

What adipotide did show, in 10 monkeys, was about 11% weight loss in a month alongside improved insulin resistance. That result is real and it is why the compound still has a market. It is also fifteen years old and still unrepeated in people. The claimed upside is covered in adipotide benefits.

What to know now

What we're watching

Watch for pages that quote the monkey weight-loss figure without the renal finding from the same study. Both came from the same ten animals, at doses tied together. A source that carries one number and drops the other is selling, not reporting.

Frequently asked questions

Does adipotide damage the kidneys?

In the 2011 rhesus monkey study, kidney markers rose with dose, and creatinine increased above 0.25 mg/kg. That is an animal finding over 28 days. No published human study has measured renal outcomes with adipotide, so the risk in people has never been quantified.

Are adipotide side effects reversible?

The published human record contains nothing on this, because the Phase I trial posted no results. Reversibility in people is not established. Any claim that effects fade after stopping is not drawn from a human dataset.

Why was the adipotide human trial stopped?

ClinicalTrials.gov lists NCT01262664 as terminated with no results posted. The registry entry does not supply a published outcome, and no paper followed. Four participants were enrolled. Anything beyond that is speculation.

Is adipotide safer at a low dose?

No human dose has an established safety profile. The trial opened at 0.03 mg/kg and ended with four enrollments and no posted data. The monkey study gave 0.43 mg/kg daily for 28 days and saw renal markers rise at the higher doses. That is reporting, not guidance.

How does adipotide's safety record compare to tirzepatide's?

They are not comparable in size. Tirzepatide's SURMOUNT-1 Phase III program and retatrutide's Phase 2 trial published adverse event data in the New England Journal of Medicine. Adipotide has four enrolled patients and no results.

References

  1. Barnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H. P., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K.-A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., & Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112. https://doi.org/10.1126/scitranslmed.3002621
  2. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 10(6), 625–632. https://doi.org/10.1038/nm1048
  3. ClinicalTrials.gov. A first-in-man, phase I evaluation of a single cycle of prohibitin targeting peptide 1 in patients with metastatic prostate cancer and obesity (NCT01262664). Terminated; no results posted. https://clinicaltrials.gov/study/NCT01262664
  4. Hong, J., & Kim, Y. H. (2022). Fatty liver/adipose tissue dual-targeting nanoparticles with heme oxygenase-1 inducer for amelioration of obesity, obesity-induced type 2 diabetes, and steatohepatitis. Advanced Science, 9(33), e2203286. https://doi.org/10.1002/advs.202203286
  5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  6. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972

every peptide, every supplier question, one library.